Elevance Health, Inc. $ELV Stake Lifted by Distillate Capital Partners LLC

Distillate Capital Partners LLC boosted its stake in Elevance Health, Inc. (NYSE:ELV) by 31.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 76,502 shares of the company’s stock after purchasing an additional 18,508 shares during the period. Elevance Health accounts for 1.3% of Distillate Capital Partners LLC’s holdings, making the stock its 19th biggest holding. Distillate Capital Partners LLC’s holdings in Elevance Health were worth $24,730,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in the stock. Nilsine Partners LLC boosted its holdings in shares of Elevance Health by 1.5% during the third quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after acquiring an additional 29 shares during the period. HBK Sorce Advisory LLC increased its holdings in shares of Elevance Health by 4.4% in the 3rd quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock worth $260,000 after acquiring an additional 31 shares during the period. Detalus Advisors LLC lifted its position in Elevance Health by 1.8% in the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock valued at $558,000 after purchasing an additional 31 shares during the last quarter. Forum Financial Management LP boosted its stake in Elevance Health by 1.1% during the 3rd quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock valued at $960,000 after purchasing an additional 33 shares during the period. Finally, Activest Wealth Management boosted its stake in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares during the period. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Stock Up 1.3%

ELV stock opened at $291.69 on Monday. The firm’s 50-day moving average is $338.25 and its two-hundred day moving average is $334.45. The company has a market capitalization of $64.38 billion, a price-to-earnings ratio of 11.61, a price-to-earnings-growth ratio of 1.61 and a beta of 0.51. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. During the same period last year, the firm posted $3.84 earnings per share. The business’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is 27.39%.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the company an “outperform” rating in a research note on Thursday, January 8th. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. UBS Group set a $400.00 price objective on Elevance Health in a report on Thursday, January 29th. Royal Bank Of Canada cut Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price on the stock. in a research report on Tuesday, February 3rd. Finally, Leerink Partners boosted their price target on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research report on Thursday, January 29th. Twelve equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Elevance Health has an average rating of “Moderate Buy” and an average price target of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.